Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.12 USD
22.72 M USD
50.00 M USD
14.20 M
About Contineum Therapeutics, Inc.
Sector
Industry
CEO
Carmine Stengone
Website
Headquarters
San Diego
Founded
2017
FIGI
BBG01M27SVP6
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CTNM is 13.79 USD — it has increased by 2.63% in the past 24 hours. Watch Contineum Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Contineum Therapeutics, Inc. stocks are traded under the ticker CTNM.
CTNM stock has fallen by −29.75% compared to the previous week, the month change is a −16.26% fall, over the last year Contineum Therapeutics, Inc. has showed a −4.90% decrease.
We've gathered analysts' opinions on Contineum Therapeutics, Inc. future price: according to them, CTNM price has a max estimate of 32.00 USD and a min estimate of 25.00 USD. Watch CTNM chart and read a more detailed Contineum Therapeutics, Inc. stock forecast: see what analysts think of Contineum Therapeutics, Inc. and suggest that you do with its stocks.
CTNM reached its all-time high on Jul 1, 2024 with the price of 22.00 USD, and its all-time low was 13.27 USD and was reached on May 6, 2024. View more price dynamics on CTNM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CTNM stock is 5.37% volatile and has beta coefficient of 2.49. Track Contineum Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Contineum Therapeutics, Inc. there?
Today Contineum Therapeutics, Inc. has the market capitalization of 351.87 M, it has decreased by −24.79% over the last week.
Yes, you can track Contineum Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Contineum Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CTNM earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.41 USD resulting in a 2.44% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Contineum Therapeutics, Inc. earnings.
Contineum Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CTNM net income for the last quarter is −10.27 M USD, while the quarter before that showed −9.01 M USD of net income which accounts for −13.96% change. Track more Contineum Therapeutics, Inc. financial stats to get the full picture.
No, CTNM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 31.00 employees. See our rating of the largest employees — is Contineum Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Contineum Therapeutics, Inc. EBITDA is −43.30 M USD, and current EBITDA margin is 32.54%. See more stats in Contineum Therapeutics, Inc. financial statements.
Like other stocks, CTNM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Contineum Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.